Basic Information
Verkazia
Regulatory Information
EMEA/H/C/004411
Authorised
July 6, 2018
July 20, 2017
7
April 25, 2023
Company Information
Drug Classification
Orphan MedicineAccelerated Assessment
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Treatment of severe vernal keratoconjunctivitis (VKC) in children from 4 years of age and adolescents.
Overview Summary
This is a summary of the European public assessment report (EPAR) for Verkazia. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Verkazia. For practical information about using Verkazia, patients should read the package leaflet or contact their doctor or pharmacist.